Alvogen’s sister company, Alvotech, is a uniquely positioned biopharmaceutical business that focuses purely on the biosimilar market with complete vertical integration from early R&D to commercial manufacturing.
Alvogen global operations includes five manufacturing facilities in the U.S., Romania, South-Korea and Taiwan. Capabilities include finished dosage form manufacturing including solid oral dosage, soft gelatin capsules, modified release tablets, transdermals, creams, ointments and injectables.
Our goal is to ensure that the benefits and risks of a medication are continuously monitored and well-understood by regulators, healthcare providers and patients. Alvogen maintains a pharmacovigilance system, collecting information over the lifecycle of each product.
Alvogen has commercial operations in more than 30 countries around the world, with regional hubs, manufacturing and R&D capabilities in the U.S., South Korea and Romania. Connect directly with our local temas for more information on products, business opportunities and more.
Alvogen has commercial operations in 35 countries, with regional hubs, manufacturing and R&D capabilities in the U.S., South Korea and Romania.